Market News AIOpen the app

Moleculin Biotech, Inc. shares news about a study on Annamycin's heart safety.

TrialRead the original at SEC EDGAR
Neutral

Moleculin said a peer-reviewed analysis examined Annamycin's heart safety in 90 patients across 5 trials. The filing gives no results, so it does not change the company's outlook.

MBRX · Moleculin Biotech, Inc.

AI read · Neutral

The AI's read

The notice gives the study's size and the diseases studied, but not what the heart-safety review found. Without those results, it does not show whether Annamycin became safer or less safe to use, so the company's outlook is unchanged.

Get alerts for MBRX

Follow Moleculin Biotech, Inc. (MBRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for MBRX
Free on the App Store and Google Play, or on the web.